WEBULL
WebtradeDownload

How FDA Cancer Wins and Tariff Relief Deal Will Impact BeOne Medicines (ONC) Investors

Simply Wall St · 2d ago
  • In late August 2026, BeOne Medicines Ltd. secured FDA approvals for TEVIMBRA and ZIIHERA-based first-line HER2+ gastroesophageal cancer regimens and entered a voluntary U.S. government agreement tying more than US$1.00 billion of onshore manufacturing investment to tariff relief and expanded access commitments.
  • This combination of first-in-class oncology approvals and a Section 232 tariff exemption could reshape BeOne’s competitive position and manufacturing economics in the U.S. market.
  • Next, we’ll examine how the FDA approval of TEVIMBRA plus ZIIHERA in first-line HER2+ GEA may reshape BeOne’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines today, you need to believe it can broaden its oncology revenue base beyond BRUKINSA while keeping R&D and pricing pressures in check. The TEVIMBRA plus ZIIHERA first‑line HER2+ GEA approval strengthens that diversification effort and adds support for near term revenue expectations, while the voluntary U.S. pricing and access commitments sharpen the key risk around future net pricing and margin pressure.

The most relevant recent development here is the U.S. FDA approval of TEVIMBRA plus ZIIHERA and chemotherapy in first line HER2+ gastroesophageal cancers. This regimen, supported by HERIZON‑GEA‑01 data showing superior overall and progression free survival versus trastuzumab plus chemotherapy, directly feeds into BeOne’s solid tumor ambitions and could influence how investors weigh its reliance on BRUKINSA against an emerging second growth pillar.

Yet beneath the oncology momentum, the real concern investors should be aware of is how future U.S. pricing and tariff shifts could...

Read the full narrative on BeOne Medicines (it's free!)

BeOne Medicines’ narrative projects $9.1 billion revenue and $1.8 billion earnings by 2029.

Uncover how BeOne Medicines' forecasts yield a $433.02 fair value, a 21% upside to its current price.

Exploring Other Perspectives

ONC 1-Year Stock Price Chart
ONC 1-Year Stock Price Chart

Some of the lowest analyst estimates were already cautious, assuming revenue growth near 10 percent a year and earnings of about US$1.0 billion by 2029, so this new approval and U.S. manufacturing deal may prompt you to rethink whether that more pessimistic pricing and margin story still holds up.

Explore 5 other fair value estimates on BeOne Medicines - why the stock might be worth just $344.15!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.